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Background
Current low-mechanical index (low-MI) techniques for contrast-enhanced ultrasound 
(CEUS) using second-generation microbubble agents have advantages in the character-
ization of focal liver lesions (FLLs), including the real-time observation of continuous 
hemodynamic changes in hepatic lesions (Claudon et al. 2013). However, to our knowl-
edge, there is little agreement concerning the appropriate injection rate for microbubble 
agents in CEUS, despite the fact that there have been many studies regarding the injec-
tion rate of contrast media in dynamic computed tomography (CT) (Tublin et al. 1999) 
and magnetic resonance (MR) imaging (Schmid-Tannwald et al. 2012).
Abstract 
Objective: To determine the optimal bolus injection rate of ultrasound (US) contrast 
agent in vascular imaging for focal liver lesions.
Methods: Thirteen patients with 13 focal liver lesions (5 hepatocellular carcinomas 
(HCCs) with cirrhosis, 4 liver metastases, 2 hemangiomas, 1 intrahepatic cholangiocar-
cinoma, 1 focal nodular hyperplasia) received two bolus injections of Sonazoid (at 0.5 
and 2.0 mL/s) using an automatic power injector. The lesion-to-liver contrast ratio at 
peak enhancement was quantitatively evaluated. Enhancement of the lesions com-
pared to liver parenchyma was assessed by two independent readers using a five-point 
scale and qualitatively evaluated by receiver operating characteristic (ROC) analysis.
Results: For all lesions, the contrast ratio was not significantly different between the 
two injection rates. For HCCs, the contrast ratio was higher at 0.5 mL/s (7.41 ± 6.56) 
than at 2.0 mL/s (4.28 ± 4.66, p = 0.025). For all lesions, the mean area under the ROC 
curve (AUC) was not significantly different between the two injection rates. For HCCs, 
the AUC was greater at 0.5 mL/s than at 2.0 mL/s (AUC: 0.86, p = 0.013).
Conclusion: In contrast-enhanced US, an injection rate of 0.5 mL/s is superior to an 
injection rate of 2.0 mL/s for the quantitative and qualitative analysis of HCCs in the 
cirrhotic liver.
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We have therefore conducted a prospective pilot study to determine both qualitatively 
and quantitatively the optimal bolus injection rate of US contrast agent in vascular imag-
ing for the evaluation of FLLs, with the ultimate goal of establishing suitable protocols 
for the examination of patients with FLLs.
Methods
Subjects
Thirteen consecutive patients (2 men and 11 women; age, 67.5  ±  10.4  years 
(mean ± standard deviation); body weight, 51.9 ± 9.4 kg; and height, 151.8 ± 8.0 cm) 
with FLLs to be evaluated by CEUS were enrolled as the subjects of this pilot study. Five 
subjects had hepatocellular carcinoma (HCC) with cirrhosis, 4 had liver metastasis (2 
from pancreatic neuroendocrine tumor and 2 from breast cancer), 2 had hemangioma, 1 
had cholangiocarcinoma, and 1 had focal nodular hyperplasia (FNH).
The diagnosis of HCC, as well as liver cirrhosis, all metastases, and cholangiocarci-
noma, was based on the findings of needle biopsy (21-gauge Majima needle; Top Surgi-
cal Manufacturing, Tokyo, Japan). The diagnosis of hemangioma and FNH was based on 
a combination of imaging findings: a classic contrast enhancement pattern observed on 
CEUS, with peripheral nodular enhancement or tiny enhancing dots in the early phase 
and persistent enhancement or centripetal fill-in enhancement in the late and postvas-
cular phases for hemangioma (Claudon et al. 2013), and with a hypervascular appear-
ance with the presence of stellate lesional vessels with a centrifugal filling direction in 
the early phase and persistent enhancement in the late and postvascular phases for FNH 
(Claudon et al. 2013).
CEUS imaging
A diagnostic US system (TSU-A500, Aplio™ 500; Toshiba Medical System Corporation, 
Tochigi, Japan) with a 3.75-MHz convex transducer (PVT-375BT; Toshiba) was used 
in this study. The imaging mode was wideband harmonic imaging (commercial name 
“Pulse subtraction”) with transmission and reception frequencies of 1.75 and 3.5 MHz, 
respectively.
All subjects were fasted overnight. All US scans were performed by the same sonolo-
gist (M.A.) with 5 years of experience in standard US and CEUS. The probe was held 
steady during acquisition while the subject was breathing shallowly and evenly in order 
to obtain a single image showing the largest plane through the lesion and including adja-
cent liver parenchyma.
A second-generation US contrast agent (Sonazoid; Daiichi-Sankyo, GE, Tokyo, 
Japan) was used. Each subject received two injections on the same day. The first bolus 
injection was 0.5  mL of Sonazoid injected at 0.5  mL/s followed by a 10-mL saline 
flush injected at the same rate, and the second bolus injection was 0.5 mL of Sonazoid 
injected at 2.0  mL/s followed by a 10-mL saline flush injected at the same rate. All 
subjects received injection into an antecubital vein via a 21-gauge intravenous catheter 
using an automatic power injector (SONAZOID SHOT™; Nemoto Kyorindo, Tokyo, 
Japan) consisting of a double syringe pump capable of injecting microbubble contrast 
agent and saline sequentially (Fig. 1). It should be noted that before the second injec-
tion, the remaining circulating microbubbles were destroyed as completely as possible 
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by performing high-MI US scanning for at least 20 min. The automatic injector system 
used in the present study supports variable injection speeds with manual or pedal con-
trol. The microbubble syringe was automatically shaken before microbubble injection 
when the system was stopped in order to ensure effective injection. The two syringes 
were connected to a T-line, and the injection speed was adjustable in the range of 
0.1–2.0 mL/s.
Examination recording and timing were triggered immediately after the contrast agent 
was injected. The acquisition time for the raw data was 1 min. The use of low-MI nonlin-
ear imaging (MI < 0.2) allowed the microbubbles to be visualized nondestructively with 
simultaneous low-MI B-mode anatomic imaging displayed side by side.
CEUS examinations were performed at a rate of 10 frames per second and with a 
dynamic range of 60 dB. The receive gain, image depth, and transmit focus were opti-
mized for each subject. When the examination was completed, the raw data were stored 
in a workstation (UltraExtend FX; Toshiba). Initial quantification was performed using 
US quantification software (CHI-Q; Toshiba).
Region of interest (ROI) analysis
After the raw data were transferred to the workstation, the data were analyzed and ROIs 
encompassing the lesions were drawn by the same hepatologist (K.S.). Similarly, a circu-
lar or oval ROI was placed in adjacent liver parenchyma at the same depth as the lesion. 
This ROI was as large as possible and placed so as to avoid vessels and artifacts. An 
example showing how the ROIs were placed is shown in Fig. 2. The time-intensity curve 
of the total surface delimited was calculated as the sum of the time-intensity curves of all 
pixels using the linear raw data obtained with the CHI-Q software.
Quantitative perfusion parameter analysis
The fitting of the curve was based on a mathematical model developed by the Gustave 
Roussy Institute (patent WO/2008/053268, “Method and System for Quantification of 
Tumoral Vascularization”), and the Solver program in Excel was used to determine the 
Fig. 1 The automatic power injector employed in the present study. It consists of a double syringe pump 
capable of injecting microbubble contrast agent (white arrow) and saline (black arrow) sequentially
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coefficients of the fitted curve based on the least squares method. This method consists 
of minimizing the differences between the parameters of the unfitted raw curve and the 
coefficients of the Gustave Roussy Institute equation (Gauthier et al. 2012):
where I(t) describes the variation in the intensity of contrast uptake as a function of 
time, a0 is the intensity before the arrival of the contrast agent, a1 is linked to the maxi-
mum value of contrast uptake, a2 is linked to the rise time to the peak intensity, p is a 
coefficient related to the increase in intensity, q is a coefficient related to the decrease in 
intensity, and A and B are arbitrary parameters.
In this study, two semiquantitative perfusion parameters were extracted from the 
time-intensity curves after modelization: the peak intensity of the FLL (in arbitrary 
units) and the time to peak intensity (in seconds). The lesion-to-liver contrast ratio was 
calculated using the following equation: the lesion-to-liver contrast ratio equals the peak 
intensity of the lesion divided by the intensity of the liver parenchyma at the time to 
peak intensity of the lesion. The definitions are shown in Fig. 3. All quantifications were 
performed by the same author (K.S.).















Fig. 2 Example of the workstation interface. A red circular region of interest is placed on the lesion (focal 
nodular hyperplasia) and a blue region of interest is placed in adjacent liver parenchyma. Time-intensity 
curves of the lesion (red curve) after modelization and of adjacent liver parenchyma (blue curve) after modeli-
zation are displayed on the right side
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Qualitative visual analysis
Two experienced sonologists (M.A. and S.O.) involved in the study qualitatively assessed 
the degree of lesion conspicuity as compared to adjacent liver parenchyma in CEUS 
images during all vascular phases. The two sonologists performed assessment indepen-
dently and were blinded to the injection rate used.
All image cine clips were reviewed at the workstation (UltraExtend FX; Toshiba). The 
degree of lesion conspicuity was visually scored in comparison to adjacent liver paren-
chyma using a five-point scale: 5 (excellent), contrast enhancement provided optimal 
information for establishing a diagnosis; 4 (good), contrast enhancement provided ade-
quate information for establishing a diagnosis; 3 (fair), contrast enhancement provided 
acceptable information for establishing a diagnosis, but image quality was unsatisfac-
tory; 2 (poor), contrast enhancement did not provide adequate information for estab-
lishing a diagnosis; and 1 (none), no enhancement was observed.
Statistical analysis
The results were expressed as mean ±  standard deviation. The quantitative perfusion 
parameter analysis results for the two injection rates were compared using the two-
tailed Student’s t test. The conspicuity of each lesion at each injection rate and for each 
reviewer was evaluated by receiver operating characteristic (ROC) analysis. The area 
under the ROC curve (AUC) was calculated for each reviewer and for each injection 
rate. The two-tailed Student’s t test was also used to test for differences in the AUCs. A p 
value of less than 0.05 was considered to be statistically significant. All statistical analy-
ses were performed using a computer software package (JMP® version 11; SAS Institute 
Japan Ltd., Tokyo, Japan).
Fig. 3 The lesion-to-liver contrast ratio is calculated using the following equation: lesion-to-liver contrast 
ratio equals “a” divided by “b”. a Peak intensity of the lesion (in arbitrary units), b intensity of the liver paren-
chyma at the time to peak intensity of the lesion, c time to peak intensity of the lesion (in seconds)
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Results
Quantitative assessment
For all lesions, no significant difference in the lesion-to-liver contrast ratio was observed 
between the two injection rates. For HCC, the contrast ratio was higher for injection at 
0.5 mL/s (7.41 ± 6.56) than for injection at 2.0 mL/s (4.28 ± 4.66, p = 0.025) (Fig. 4). The 
time to peak intensity was significantly shorter for injection at 2.0 mL/s (21.6 ± 6.0 s) 
than for injection at 0.5 mL/s (27.1 ± 4.1 s, p = 0.0057).
ROC analysis
For all lesions, no significant difference in the mean AUC was observed between the two 
injection rates. For HCC, the mean AUC was greater for injection at 0.5 mL/s than for 
injection at 2.0 mL/s (AUC: 0.86, p = 0.013) (Fig. 4).
Discussion
An important advantage of CEUS is the ability to assess contrast enhancement patterns 
in real time with a much higher temporal resolution than is possible with other imaging 
modalities. It may therefore seem that there is no need to define an optimal injection 
protocol, unlike the case for CT or MR imaging.
In fact, one set of clinical CEUS guidelines for the liver simply states that ultrasound 
contrast agent should be administered as a bolus injection followed by a 0.9 % normal 
saline flush (Claudon et al. 2013). Another states that contrast agent should be admin-
istered by bolus injection within 2 s, followed by flushing with 10 mL of normal saline 
(Jang et  al. 2013). We basically agree with these guidelines, but we also feel that it is 
important to conduct studies to determine whether it is possible to develop optimal 
CEUS examination protocols, particularly with regard to the injection of contrast agent.
The results of this pilot study showed that, for all lesions, no significant differences 
were observed between the two injection rates in both quantitative and qualitative anal-
ysis. However, for HCC in the cirrhotic liver, an injection rate of 0.5 mL/s was found to 
be significantly superior to an injection rate of 2.0 mL/s in both quantitative and qualita-
tive analysis.
Elucidating the mechanisms responsible for the finding that a slow injection rate is 
superior only for HCC in patients with a cirrhotic liver may be important in CEUS 
examinations for the characterization of FLLs. In general, it is said that as the liver 
becomes cirrhotic, the hepatic blood flow balance changes from “portal vein domi-
nant” to “hepatic artery dominant” (Kleber et al. 1999). Thus, we assume that the arterial 
enhancement of HCC can be masked by that of adjacent liver parenchyma and that this 
phenomenon is expressed more strongly at a faster injection rate because the time to 
peak intensity is significantly shorter for a fast injection rate than a slow injection rate. 
Our visual assessment and ROC analysis results support this theory.
Our study has several limitations. First, the number of subjects was relatively small, 
although the number is probably sufficient for a pilot study. Second, pathologic confir-
mation was not obtained for a minority of the lesions, although all subjects did undergo 
confirmatory imaging examinations.
In conclusion, in CEUS examinations, an injection rate of 0.5 mL/s was found to be 
significantly superior to an injection rate of 2.0 mL/s for the quantitative and qualitative 
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Fig. 4 Images of an 81-year-old woman with liver cirrhosis and a hepatocellular carcinoma (HCC) in segment 
4. A Sonazoid is injected at a rate of 0.5 mL/s. The CEUS image at peak enhancement shows clear hypervas-
cularity; the resulting average visual rating is 4.5 (reader 1: 4, reader 2: 5). A red circular region of interest is 
placed on the HCC and a blue region of interest is placed in adjacent liver parenchyma. The lesion-to-liver 
contrast ratio is 4.70. B Sonazoid is injected at a rate of 2.0 mL/s. The CEUS image at peak enhancement 
shows isovascularity to slight hypervascularity; the resulting average visual rating is 3 (reader 1: 3, reader 2: 3). 
A red circular region of interest is placed on the HCC and a blue region of interest is placed in adjacent liver 
parenchyma. The lesion-to-liver contrast ratio is 1.80
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analysis of HCC in the cirrhotic liver. The use of a slow injection rate may improve the 
diagnostic accuracy of CEUS for HCC in patients with cirrhosis of the liver.
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